Leiomyomatosis and renal cell cancer, hereditary

Search Trials
A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)
Status:
Recruiting
Last Changed:
Aug 7, 2019
First Changed:
Apr 5, 2019
Disease(s):
Progressive Familial Intrahepatic Cholestasis (PFIC)
Intervention(s):
MaralixibatPlacebo
A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)
Status:
Withdrawn
Last Changed:
Mar 18, 2019
First Changed:
Nov 27, 2017
Disease(s):
Progressive Familial Intrahepatic Cholestasis (PFIC)
Intervention(s):
MaralixibatPlacebo
Second-line Therapy of Unresectable Cholangiocarcinoma by RADIOEMBOLIZATION
Status:
Terminated
Last Changed:
Aug 7, 2013
First Changed:
Jun 28, 2011
Disease(s):
Cholestasis, Progressive Familial Intrahepatic 3
Intervention(s):
Yttrium microsphere injection
Hereditary Leiomyomatosis Renal Cell Cancer – Study of the Genetic Cause and the Predisposition to Renal Cancer
Status:
Recruiting
Last Changed:
Aug 9, 2018
First Changed:
Dec 18, 2002
Disease(s):
Renal Tumor Histology
Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
Status:
Recruiting
Last Changed:
Jun 19, 2019
First Changed:
Jul 13, 2015
Disease(s):
Renal Cell Carcinoma
Intervention(s):
VandetanibMetforminVandetanib/Metformin

Connect. Empower. Inspire.